Champions Oncology (CSBR) Earnings Analysis
Champions Oncology (CSBR) next reports earnings on 2026-07-27, consensus EPS -0.05 USD. Last quarter (2026-03-12) it missed with EPS -0.02 USD vs 0.09 USD est (-122.2%). It has beaten estimates in 3/7 recent quarters (43%). Trailing P/E -37.79.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CSBR next report earnings?
| Next earnings date | 2026-07-27 |
|---|---|
| Consensus EPS estimate | -0.05 USD |
| Revenue estimate | 0.01B |
CSBR earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-12 | -0.02 USD | 0.09 USD | -122.2% | Miss |
| 2025-12-15 | 0.02 USD | 0.08 USD | -75% | Miss |
| 2025-09-15 | -0.03 USD | 0.01 USD | -400% | Miss |
| 2025-07-23 | -0.13 USD | 0.06 USD | -316.7% | Miss |
| 2025-03-11 | 0.31 USD | -0.01 USD | +3200% | Beat |
| 2024-12-11 | 0.05 USD | 0.01 USD | +400% | Beat |
| 2024-09-11 | 0.11 USD | 0.01941 USD | +466.7% | Beat |
Beat rate: 3/7 (43%) over reported quarters with consensus data.
CSBR valuation and analyst view
| Trailing P/E | -37.79 |
|---|---|
| Trailing EPS | -0.16426 USD |
| Price / book | 19.88 |
| Dividend yield | 0.00% |
| Market cap | 0.08B |
| Analyst consensus | Buy (5 buy / 2 hold / 0 sell) |
Related research pages
Frequently asked questions
When is Champions Oncology (CSBR)'s next earnings date?
Champions Oncology is next scheduled to report on 2026-07-27, with a consensus EPS estimate of -0.05 USD and revenue estimate of 0.01B.
Did CSBR beat earnings last quarter?
In its 2026-03-12 report, CSBR posted EPS of -0.02 USD versus a 0.09 USD estimate — a miss of 122.2%.
What is CSBR's earnings track record?
Over the last 7 reported quarters with consensus data, CSBR beat estimates 3 times (43%).
What is CSBR's current P/E ratio and EPS?
CSBR trades at a trailing P/E of -37.79 on trailing EPS of -0.1642567396931056 USD.
What do analysts rate CSBR?
Analyst consensus is "Buy" across 7 ratings (0 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell).